Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?

Novo Nordisk (NVO) shares have fallen 19.9% year-to-date, primarily due to disappointing late-stage data for its obesity candidate CagriSema, Medicare's decision not to cover weight-loss drugs, and intensifying competition from Eli Lilly's GLP-1 offerings like Zepbound, compounded by an executive leadership transition. Despite these headwinds, NVO reported an 83% surge in Q1 2025 Wegovy sales, is actively expanding semaglutide indications, investing in manufacturing capacity, and advancing a robust next-generation pipeline, signaling continued long-term potential in the rapidly expanding obesity market. The article suggests the current stock downturn may present a strategic entry point for long-term investors, given NVO's strong fundamentals and market leadership.

Analysis

Novo Nordisk (NVO) is facing significant headwinds, reflected in a 19.9% year-to-date stock price decline, driven by multiple factors. Key among these are disappointing late-stage trial data for its next-generation obesity candidate, CagriSema, which showed lower-than-expected efficacy, and a significant regulatory setback from Medicare's decision not to cover weight-loss drugs like Wegovy. Compounding these issues is intensifying competition from Eli Lilly (LLY), whose drug Zepbound demonstrated superior weight-loss results in a head-to-head study (20.2% vs. 13.7% for Wegovy), alongside LLY's progress with a promising oral GLP-1 candidate. The impending departure of CEO Lars Fruergaard Jørgensen adds leadership uncertainty. Despite these challenges, NVO's underlying business remains robust. Wegovy sales surged 83% in Q1 2025, and the company maintains a dominant 54% global market share in the GLP-1 segment. Strategic wins, such as CVS Caremark designating Wegovy as a preferred therapy, and aggressive label expansion into cardiovascular indications, are broadening the drug's addressable market. While the stock's forward P/E of 16 is at a premium to the industry, it is substantially below its five-year average of 29.25, and the company's return on equity is a formidable 80.95%, indicating strong operational efficiency. The pipeline remains active with candidates like Amycretin, signaling a long-term strategy beyond current setbacks in a market projected to reach $100 billion by 2030.

Key Decisions for Investors

• Given the stock's valuation has reset to a forward P/E of 16, significantly below its historical average, long-term investors could view the current price weakness as a strategic opportunity to gain exposure to strong underlying growth and high return on equity.
• Investors must closely monitor the competitive dynamics with Eli Lilly, specifically tracking prescription trends and market share data for Wegovy versus Zepbound, as well as progress on LLY's oral obesity pipeline, which represents a primary risk to NVO's market leadership.
• Anticipate continued near-term volatility due to the ongoing CEO transition and the upcoming FDA decision on oral semaglutide; it may be prudent to await clarity on these catalysts before initiating or adding to positions, particularly for those with shorter investment horizons.